Last reviewed · How we verify
Rivoceranib Mesylate, Paclitaxel
At a glance
| Generic name | Rivoceranib Mesylate, Paclitaxel |
|---|---|
| Sponsor | Asan Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor (PHASE2)
- A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rivoceranib Mesylate, Paclitaxel CI brief — competitive landscape report
- Rivoceranib Mesylate, Paclitaxel updates RSS · CI watch RSS
- Asan Medical Center portfolio CI